Brief: China Grand Pharmaceutical And Healthcare Says Obtained Commercialization Rights Of An Epinephrine Auto-Injector
02/08/2021 14:15
Aug 2 (Reuters) - China Grand Pharmaceutical and Healthcare
Holdings Ltd 0512.HK :
* GROUP OBTAINED COMMERCIALIZATION RIGHTS OF AN EPINEPHRINE
AUTO-INJECTOR FOR TREATMENT OF ANAPHYLAXIS
* RIGHTS OBTAINED FOR MAINLAND CHINA, MACAU AND TAIWAN
* TOTAL DOWN-PAYMENT AND MILESTONE PAYMENT OF EUR12 MILLION
Source text for Eikon: ID:nHKS9k3C4J
Further company coverage: 0512.HK
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement